Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    In-Person

    Methylphenidate primed iTBS for apathy in neurocognitive disorders

    What is this Study about?

    Apathy, or reduced interest, initiative and emotion, is common in people living with Alzheimer’s disease and can affect quality of life and functioning. This study will test whether combining methylphenidate, an oral medication, with intermittent theta burst stimulation (iTBS), a non-invasive brain stimulation treatment, is more effective than iTBS alone for treating apathy in dementia. Information collected will help determine whether this combined approach may improve apathy and quality of life for people living with dementia and their care partners.

    Eligibility Criteria

    • Have Alzheimer’s disease or mixed Alzheimer’s/vascular disease of mild to moderate severity
    • Have apathy, such as less interest, initiative or emotion, for at least 4 weeks at the screening visit
    • Have been taking a stable dose for at least 4 weeks of any medication that affects thinking or behaviour
    • Have a care partner who spends at least 10 hours per week with you and can accompany you to study visits

    Recruitment End Date

    Find Out More
  • Observational Study
    In-person & Online

    Hospitalization Experiences of South Asian and Arab Older Adults with Dementia and Their Caregivers

    What is this Study about?

    This study aims to explore the hospitalization experiences of South Asian and Arab older adults with dementia and identify barriers and facilitators they encounter during their hospital stay in receiving culturally safe care. The information gathered will be used to identify gaps in current hospital dementia care practices and create resources and recommendations for policy and practice changes that promote culturally safe, inclusive dementia care for ethnic communities.

    Eligibility Criteria

    You are eligible to participate if you are:

    Older Adults:

    • an older adult aged 60 years or older
    • from the South Asian or Arab community
    • living in Edmonton
    • living with a diagnosis of dementia or currently undergoing the diagnostic process
    • currently hospitalized or have experienced hospitalization within the past year

    Caregivers

    • from the South Asian or Arab community
    • involved in caring for a family member living with dementia during hospitalization and hospital stay

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Non-invasive brain stimulation to improve working memory in dementia: a proof-of-concept study

    What is this Study about?

    This study is exploring the viability of a potential treatment for cognitive decline in dementia by attempting to improve the brain's ability to hold onto information temporarily while doing things like reading lists, having a conversation, or problem-solving. The results from this study will inform future research in improving working memory and cognition in people living with dementia.

    Eligibility Criteria

    You are eligible to participate if you are:

    1) Diagnosed with Dementia and/or memory loss by a clinician

    2) Exhibit adequate oral communication skills and cognitive function sufficient to obtain a score over 10 on the Mini-Mental State Exam

    3) Over the age of 55

    4) Speaks English

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Levetiracetam for Persons at Risk for Alzheimer's Disease (ALEVIATE-2)

    What is this Study about?

    The goal of this study is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in the brain in individuals who are at an increased risk for developing Alzheimer's Disease. Only participants who show the abnormal brain signaling on a functional MRI (fMRI) scan of the brain will be enrolled in the study. Enrolled participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill). The study involves cognitive testing, genetic testing, bloodwork, ECGs, questionnaires and several brain imaging scans.

    Eligibility Criteria

    • Are between 55-85 years of age

    • Have a parent or sibling with Alzheimer’s disease or with dementia that may be due to Alzheimer’s disease (even if not diagnosed as such)

    • Feel your memory is getting worse

    • Get normal scores on tests of thinking and memory (will be done as part of the study)

    • Are able to undergo brain MRI scans

    • Have a study partner (friend or family member) willing to answer questionnaires about you

    • Show increased brain signaling during the screening fMRI scan (Note: We anticipate that most people who sign up for the study will NOT show the increased brain activity levels required to qualify for the study treatment)

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease Psychosis

    What is this Study about?

    ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).

    The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

    Eligibility Criteria

    Male or female participants aged 55 to 90 years of age
    Must have a study partner
    Presence of psychotic symptoms for at least 2 months before Screening.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)

    What is this Study about?

    The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

    Eligibility Criteria

    Male or female participants aged 50 years of age
    Has a history of previous clinical intracerebral hemorrhage.
    Has probable CAA.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

    What is this Study about?

    This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    What is this Study about?

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 55 years of age to 90.
    Must have a study partner
    History of agitation due to AD.

    Recruitment End Date

    Find Out More